-
1.发明申请A STABILIZED DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF RABEPRAZOLE 审中-公开稳定的延迟释放RABEPRAZOLE药物组合物
公开(公告)号：WO2008129517A3
公开(公告)日：2009-05-07
申请号：PCT/IB2008051568
申请日：2008-04-24
Applicant: RANBAXY LAB LTD , ISSA CHAYAPATHY , MANGAT PUNEET , GANDHI RAJESH , SINGH ROMI BARAT , MATHUR RAJEEV SHANKER
Inventor： ISSA CHAYAPATHY , MANGAT PUNEET , GANDHI RAJESH , SINGH ROMI BARAT , MATHUR RAJEEV SHANKER
IPC: A61K9/28 , A61K31/4439
CPC classification number: A61K9/2886 , A61K9/2866 , A61K31/4439
Abstract: The invention relates to a stabilized delayed release pharmaceutical composition of rabeprazole comprising: a. a tablet core comprising rabeprazole or pharmaceutically acceptable salt thereof, sodium carbonate and a. disintegrant selected from the group consisting of crospovidone and low substituted hydroxypropylcelullose; b. a seal coating comprising ethyl cellulose and a disintegrant selected from the group consisting of crospovidone and low substituted hydroxypropylcelullose; and c. an enteric coating.
Abstract translation: 本发明涉及雷贝拉唑稳定的延迟释放药物组合物，其包含：a。 包含雷贝拉唑或其药学上可接受的盐的片芯，碳酸钠和a。 崩解剂选自交聚维酮和低取代羟丙基纤维素; 湾 包含乙基纤维素的密封涂层和选自交聚维酮和低取代羟丙基纤维素的崩解剂; 和c。 肠溶衣。
-
2.发明申请Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide 审中-公开制备缬沙坦和氢氯噻嗪固体剂型的方法
公开(公告)号：WO2005082329B1
公开(公告)日：2006-06-08
申请号：PCT/IB2005000340
申请日：2005-02-10
Applicant: RANBAXY LAB LTD , SINGH ROMI BARAT , KARANTH GIRISH , NAGAPRASAD VISHNUBHOTLA
Inventor： SINGH ROMI BARAT , KARANTH GIRISH , NAGAPRASAD VISHNUBHOTLA
IPC: A61K9/24 , A61K9/20 , A61K31/41 , A61K31/549 , A61K45/06
CPC classification number: A61K9/209 , A61K9/2077 , A61K31/41 , A61K31/549 , A61K2300/00
Abstract: The present invention relates to solid dosage forms comprising valsartan in a core and hydrochlorthiazide (HCTZ) in a coating layer; and process of preparation thereof.
Abstract translation: 本发明涉及包含核心中的缬沙坦和涂层中的氢氯噻嗪（HCTZ）的固体剂型; 及其制备方法。
-
3.发明申请PROCESS FOR THE PREPARATION OF SOLID DOSAGE FORMS OF VALSARTAN AND HYDROCHLORTHIAZIDE 审中-公开制备VALSARTAN和氢氯噻嗪类固体剂型的方法
公开(公告)号：WO2005082329A2
公开(公告)日：2005-09-09
申请号：PCT/IB2005000340
申请日：2005-02-10
Applicant: RANBAXY LAB LTD , SINGH ROMI BARAT , KARANTH GIRISH , NAGAPRASAD VISHNUBHOTLA
Inventor： SINGH ROMI BARAT , KARANTH GIRISH , NAGAPRASAD VISHNUBHOTLA
CPC classification number: A61K9/209 , A61K9/2077 , A61K31/41 , A61K31/549 , A61K2300/00
Abstract: The present invention relates to solid dosage forms comprising valsartan in a core and hydrochlorthiazide (HCTZ) in a coating layer; and process of preparation thereof.
Abstract translation: 本发明涉及包含核心中的缬沙坦和涂层中的氢氯噻嗪（HCTZ）的固体剂型; 及其制备方法。
-
4.发明申请PHARMACEUTICAL COMPOSITIONS OF NATEGLINIDE AND A HIGH AMOUNT OF A WATER-SOLUBLE FILLER 审中-公开N-乙酰胆碱的药物组合物和大量的水溶性填料
公开(公告)号：WO2005016315A1
公开(公告)日：2005-02-24
申请号：PCT/IB2004/002654
申请日：2004-08-13
Applicant: RANBAXY LABORATORIES LIMITED , SINGH, Romi, Barat , SHILPA, Anu , NAGAPRASAD, Vishnubhotla , SETHI, Sanjeev, Kumar
Inventor： SINGH, Romi, Barat , SHILPA, Anu , NAGAPRASAD, Vishnubhotla , SETHI, Sanjeev, Kumar
IPC: A61K9/20
CPC classification number: A61K31/00 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054
Abstract: The present invention relates to pharmaceutical compositions of Nateglinide with 50-70% of water-soluble filler such as lactose alone or in combination with a channeling agent such as sodium chloride or compressible sugar. These compositions may have a dissolution profile wherein at least 70% by weight of Nateglinide is released within 45 minute period.
Abstract translation: 本发明涉及那格列奈的药物组合物，其具有50-70％的水溶性填料，例如单独的乳糖或与窜流剂如氯化钠或可压缩糖组合。 这些组合物可具有溶解曲线，其中至少70重量％的那格列奈在45分钟内释放。
-
公开(公告)号：WO2013018050A3
公开(公告)日：2013-02-07
申请号：PCT/IB2012/053945
申请日：2012-08-01
Applicant: RANBAXY LABORATORIES LIMITED , VATS, Sandeep, Kumar , KALAISELVAN, Ramaraju , SINGH, Romi, Barat
Inventor： VATS, Sandeep, Kumar , KALAISELVAN, Ramaraju , SINGH, Romi, Barat
Abstract: The present invention relates to controlled-release pharmaceutical dosage forms comprising a solid dispersion of a poorly water-soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled-release dosage forms.
-
Patent Agency Ranking6.发明申请DISSOLUTION ENHANCED CONTROLLED DRUG DELIVERY SYSTEM FOR POORLY WATER SOLUBLE DRUGS 审中-公开解决不完善的水溶性药物增强控制药物输送系统
公开(公告)号：WO2013018050A2
公开(公告)日：2013-02-07
申请号：PCT/IB2012053945
申请日：2012-08-01
Applicant: RANBAXY LAB LTD , VATS SANDEEP KUMAR , KALAISELVAN RAMARAJU , SINGH ROMI BARAT
Inventor： VATS SANDEEP KUMAR , KALAISELVAN RAMARAJU , SINGH ROMI BARAT
IPC: A61K9/14
CPC classification number: A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2045 , A61K9/2866 , A61K9/4808 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K31/41 , A61K31/546
Abstract: The present invention relates to controlled-release pharmaceutical dosage forms comprising a solid dispersion of a poorly water-soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled-release dosage forms.
Abstract translation: 本发明涉及控释药物剂型，其包含难溶性或不溶性药物的固体分散体，其具有改善的溶解性并因此改善了在水性介质中的溶解度。 本发明进一步公开了这些控制释放剂型的制备方法。
-
公开(公告)号：WO2013001516A1
公开(公告)日：2013-01-03
申请号：PCT/IB2012/053341
申请日：2012-06-29
Applicant: RANBAXY LABORATORIES LIMITED , BHAVARISETTI, Murali, Krishna , VIVEK, Kumaravel , NARRAVULA, Sreekanth , SINGH, Romi, Barat
Inventor： BHAVARISETTI, Murali, Krishna , VIVEK, Kumaravel , NARRAVULA, Sreekanth , SINGH, Romi, Barat
IPC: A61K9/20 , A61K31/137 , A61K31/138 , A61K31/366 , A61K31/445 , A61K31/455 , A61K31/55
CPC classification number: A61K9/209 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/366 , A61K31/445 , A61K31/455 , A61K31/55 , A61K31/554
Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.
Abstract translation: 本发明涉及包含至少三层，即第一层，第二层和第三层的多层涂层片，其中第一层和第三层含有至少一种活性药物成分，第二层是安慰剂或立即释放药物 层。 此外，片剂具有延迟释放涂层，其中涂层可以在一侧或两侧上含有一个或多个成孔剂和/或孔。 此外，其可以含有延迟释放涂层上的药物的立即释放层。 本发明还涉及制备这种多层涂布片剂的方法。
-
公开(公告)号：WO2011013082A1
公开(公告)日：2011-02-03
申请号：PCT/IB2010/053439
申请日：2010-07-28
Applicant: RANBAXY LABORATORIES LIMITED , JAIN, Paras , BARABDE, Umesh, Vinayakrao , BAKSHI, Kanwarpreet, Singh , VERMA, Rajan, Kumar , SINGH, Romi, Barat
Inventor： JAIN, Paras , BARABDE, Umesh, Vinayakrao , BAKSHI, Kanwarpreet, Singh , VERMA, Rajan, Kumar , SINGH, Romi, Barat
IPC: A61K9/50 , A61K31/137
CPC classification number: A61K9/5078 , A61K9/5047 , A61K31/137
Abstract: The invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof.
Abstract translation: 本发明涉及包含多层多单元的药物组合物及其制备方法。
-
9.发明申请A STABILIZED DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF RABEPRAZOLE 审中-公开稳定的延迟释放RABEPRAZOLE药物组合物
公开(公告)号：WO2008129517A2
公开(公告)日：2008-10-30
申请号：PCT/IB2008/051568
申请日：2008-04-24
Applicant: RANBAXY LABORATORIES LIMITED , ISSA, Chayapathy , MANGAT, Puneet , GANDHI, Rajesh , SINGH, Romi, Barat , MATHUR, Rajeev, Shanker
Inventor： ISSA, Chayapathy , MANGAT, Puneet , GANDHI, Rajesh , SINGH, Romi, Barat , MATHUR, Rajeev, Shanker
IPC: A61K9/28 , A61K31/4439
CPC classification number: A61K9/2886 , A61K9/2866 , A61K31/4439
Abstract: The invention relates to a stabilized delayed release pharmaceutical composition of rabeprazole comprising: a. a tablet core comprising rabeprazole or pharmaceutically acceptable salt thereof, sodium carbonate and a. disintegrant selected from the group consisting of crospovidone and low substituted hydroxypropylcelullose; b. a seal coating comprising ethyl cellulose and a disintegrant selected from the group consisting of crospovidone and low substituted hydroxypropylcelullose; and c. an enteric coating.
Abstract translation: 本发明涉及雷贝拉唑稳定的延迟释放药物组合物，其包含：a。 包含雷贝拉唑或其药学上可接受的盐的片芯，碳酸钠和a。 崩解剂选自交聚维酮和低取代羟丙基纤维素; 湾 包含乙基纤维素的密封涂层和选自交聚维酮和低取代羟丙基纤维素的崩解剂; 和c。 肠溶衣。
-
10.发明申请PHARMACEUTICAL COMPOSITIONS OF CANDESARTAN CILEXETIL STABILIZED WITH CO-SOLVENTS 审中-公开用共溶剂稳定的CANDESARTAN CILEXETIL的药物组合物
公开(公告)号：WO2005070398A8
公开(公告)日：2006-05-04
申请号：PCT/IB2005000156
申请日：2005-01-21
Applicant: RANBAXY LAB LTD , SINGH ROMI BARAT , KARANTH GIRISH K , PRASAD VISHNUBHOTLA NAGA
Inventor： SINGH ROMI BARAT , KARANTH GIRISH K , PRASAD VISHNUBHOTLA NAGA
CPC classification number: A61K9/2866 , A61K9/2059 , A61K31/41 , A61K2300/00
Abstract: The present invention relates to stable pharmaceutical compositions that include candesartan cilexetil and one or more co-solvents.
Abstract translation: 本发明涉及稳定的药物组合物，其包含坎地沙坦西酯和一种或多种共溶剂。
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.012 seconds)
